Form 8-K - Current report:
SEC Accession No. 0001437749-22-010872
Filing Date
2022-05-04
Accepted
2022-05-04 16:41:38
Documents
15
Period of Report
2022-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dmtp20220503_8k.htm   iXBRL 8-K 28764
2 EXHIBIT 99.1 ex_370055.htm EX-99.1 139119
7 logo01.jpg GRAPHIC 9893
  Complete submission text file 0001437749-22-010872.txt   328628

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dmtp-20220504.xsd EX-101.SCH 3600
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dmtp-20220504_def.xml EX-101.DEF 11516
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE dmtp-20220504_lab.xml EX-101.LAB 15383
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dmtp-20220504_pre.xml EX-101.PRE 11672
9 EXTRACTED XBRL INSTANCE DOCUMENT dmtp20220503_8k_htm.xml XML 2561
Mailing Address TWO CARLSON PARKWAY SUITE 260 MINNEAPOLIS MN 55447
Business Address TWO CARLSON PARKWAY SUITE 260 MINNEAPOLIS MN 55447 (763) 496-5454
DiaMedica Therapeutics Inc. (Filer) CIK: 0001401040 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36291 | Film No.: 22892182
SIC: 2834 Pharmaceutical Preparations